A detailed history of Stone X Group Inc. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Stone X Group Inc. holds 15,573 shares of HRMY stock, worth $544,120. This represents 0.03% of its overall portfolio holdings.

Number of Shares
15,573
Previous 20,779 25.05%
Holding current value
$544,120
Previous $715,000 27.69%
% of portfolio
0.03%
Previous 0.05%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

SELL
$32.18 - $40.46 $167,529 - $210,634
-5,206 Reduced 25.05%
15,573 $517,000
Q4 2024

Feb 12, 2025

BUY
$31.86 - $41.49 $60,438 - $78,706
1,897 Added 10.05%
20,779 $715,000
Q3 2024

Nov 12, 2024

BUY
$30.0 - $39.95 $566,460 - $754,335
18,882 New
18,882 $755,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.07B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.